About | Free Trial

Last Update

2015-03-21T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong John Kastelein?

Dr. John Kastelein J.P.

President

National Scientific Committee on Familial Hypercholesterolemia

National Scientific Committee on Familial Hypercholesterolemia

Background Information

Employment History

Lead Researcher
ENHANCE

Part of the Department of Vascular Medicine
Lipid Research Clinic

Professor of Medicine and Chairman of the Department of Vascular Medicine
Academic Medical Center

Founder of the Lipid Research Clinic
Academic Medical Center

Member, Department of Vascular Medicine
Academic Medical Center

President
Dutch Atherosclerosis Society

Professor of Medicine and Chairman of the Department of Vascular Medicine
UAMS

Member, Department of Vascular Medicine
UAMS

Professor of Medicine, Strategic Chair of Genetics of Cardiovascular Disease
UAMS

Affiliations

Board Member
International Task Force for CHD Prevention

Member
European Atherosclerosis Society

Chairman, Scientific and Clinical Advisory Board
Dezima Pharma BV

Founder
Dezima Pharma BV

Member
Royal Dutch Society for Medicine & Physics

Member
Council for Basic Science of the American Heart Association

Number of Executive and Steering Committees
IDEAL

Number of Executive and Steering Committees
ENHANCE

Executive Board
International Atherosclerosis Society

Founder
Lipid Research Clinic

Education

M.D.

Ph.D

medical degree and internal medicine

MD

PhD

Ph.D.

PhD et

medical degree

doctorate ( cum laude )

Web References (180 Total References)


Catabasis

www.catabasis.com [cached]

John Kastelein, M.D., Ph.D, FESC University of Amsterdam

Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia. Dr. Kastelein was awarded a doctorate in Medicine (with Honours) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and also a Fellow of the European Society of Cardiology (FESC). In 2010 he was awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Parel for his research in the field of gene therapy.


CETP as a Therapeutic Target | NLA vClinic

lipid.realcme.com [cached]

John J.P. Kastelein, MD PhD, FESC Professor of Medicine Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam

...
John J.P. Kastelein, MD PhD, FESC John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.
...
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72. Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet. Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal. He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators


Scientific and Clinical Advisory Boards

www.dezimapharma.com [cached]

Prof. John Kastelein, MD, PhD - Chairman Scientific and Clinical Advisory Board Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam with a research interest in ethiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesteroleamia and low HDL cholesterol. He is founder of Dezima Pharma and co-founder of UniQure and Xenon Pharma. John is advisor to Large Pharma and biotech companies developing cardiovascular disease drugs and principal investigator and advisor to many of the studies trialing new anti-dyslipidemia compounds, including CETP inhibitors. John is member of several national and international medicine, atherosclerosis and cardiology societies aiming to study, prevent and treat cardiovascular diseases. He has published several hundreds of research papers and handbooks on dyslipidemia.


Grassley's letter cites testy e-mails to ...

timesunion.com [cached]

Grassley's letter cites testy e-mails to Schering-Plough executives from ENHANCE's lead researcher, Dr. John Kastelein.In one last July, Kastelein states that if it is true the study results wouldn't be presented at an upcoming medical conference, "our collaboration is over... this starts smelling like extending the publication for no other (than) political reasons."

Kastelein went further the next day, Grassley wrote.
...
Kastelein said, according to Grassley


Omthera Pharmaceuticals - Scientific Advisory Board

ir.omthera.com [cached]

John J.P. Kastelein M.D., Ph.D.

John J.P. Kastelein (1954) is Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease.
He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof. Dr. M.R. Hayden.
Upon his return to the Netherlands, he was awarded a doctorate (Cum Laude) and in 1989 he founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam, which is currently serving as a tertiary referral centre for over 5,000 patients each year and has become part of the Department of Vascular Medicine.
In 1995, Dr. Kastelein set up a foundation for the active identification of patients with classical familial hypercholesterolaemia (FH) in the Netherlands (StoeH), for which he currently holds a position in the Board of Directors. This program has now been fully institutionalized and is operational under supervision of the RijksInstituut voor Volksgezondheid en Milieu (RIVM) and financially supported by the Ministry of Health with a total grant of approximately 30 million Euros. Since its inception, the StoeH has found over 27,000 individuals for whom a molecular diagnosis of FH could be made. The subsequent improvement of the treatment of these FH carriers has saved many lives, as published in Lancet in 2001 and very recently in the British Medical Journal in 2008.
In 1997 and 1998 he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia, Vancouver, Canada. In these years, Dr. Kastelein was a Co-Founder of Xenon Genetics Inc., a drug discovery company that has now changed its name into Xenon Pharmaceuticals Inc. and is based in Vancouver, Canada. Dr. Kastelein is president of the Dutch Atherosclerosis Society (DAS) and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS).
Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008.
Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease.
He has published over 670 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72.
Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endeavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease.
Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet.
Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has led to the recognition of the AMC as the world-wide leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the setup of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the Director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject.
He has directed 36 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators.

Similar Profiles

Other People with this Name

Other people with the name Kastelein

Marco Kastelein
Planje Accountants en Meer

Jenna Kastelein
Trinity Western University Student Association

Richard Kastelein
Blockchain Technologies Corp

Corina Kastelein
Jaguar

Robert Kastelein
Merck & Co. , Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory